Maura Hagan, MD
Hematology & Oncology · Mechanicsville, VANPI 1699738260
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,289 of the $6,266 with a category attached, or 84.4%. It is spread thinly across 54 manufacturers, the largest accounting for just 9.8% — the pattern of someone who eats at a lot of different presentations.
Across 244 payments — averaging $25.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene USA, Inc.$615
- Novartis$610
- Astellas Pharma US Inc$411
- AstraZeneca$391
- Johnson & Johnson$330
- Merck$248
- plus $4K from 48 others
Across 1 payment — averaging $4400.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$4K
What the payments were for
- Consulting fees$5258%
- Food & beverage$5,28984%
- Education$4517%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRUKINSA$525
- IMDELLTRA (AMG 757)$127
- Venclexta$110
How this compares
$6,266 in reported general payments places this provider in the 80th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 63 | $905,903 |
| ImbruvicaIbrutinib | 44 | $677,470 |
| RevlimidLenalidomide | 32 | $622,481 |
| Lenalidomide | 44 | $581,267 |
| PomalystPomalidomide | 23 | $528,389 |
| TasignaNilotinib Hcl | 25 | $492,653 |
| KisqaliRibociclib Succinate | 23 | $392,667 |
| SprycelDasatinib | 27 | $350,041 |
| XtandiEnzalutamide | 20 | $268,455 |
| LonsurfTrifluridine/Tipiracil Hcl | 15 | $216,609 |
| JakafiRuxolitinib Phosphate | 11 | $151,552 |
| EliquisApixaban | 86 | $74,792 |
| XareltoRivaroxaban | 66 | $74,288 |
| OrgovyxRelugolix | 11 | $32,680 |
| OxycontinOxycodone Hcl | 16 | $20,250 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $615 | $905,90363 claims |
| NovartisTasigna, Kisqali | $610 | $885,32048 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $180 | $878,43150 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $105 | $677,47044 claims |
| Bristol Myers SquibbRevlimid | $122 | $622,48132 claims |
| Astellas Pharma US IncXtandi | $411 | $268,45520 claims |
| Taiho Oncology, Inc.Lonsurf | $139 | $216,60915 claims |
| Incyte CorporationJakafi | $232 | $151,55211 claims |
| PfizerEliquis | $238 | $74,79286 claims |
| Johnson & JohnsonXarelto | $330 | $74,28866 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $32 | $32,68011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Mechanicsville
- Ruby KochharHampton$236K
- Victor YazbeckRichmond$190K
- David ChangNewport News$141K
- William ErshlerFairfax$139K
- Yue ZhangVirginia Beach$105K
- Jerome GoldschmidtChristiansburg$105K
- Attique SamdaniRichmond$104K
- Gary SimmonsNorfolk$82K
- Mark FlemingHampton$71K
- Sekwon JangFairfax$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.